NIA and the National Plan to Address Alzheimer's Disease
Fighting Alzheimer’s disease and related dementias is a priority at the National Institutes of Health (NIH) and other federal agencies, across the nation, and throughout much of the world. In the United States, attention to Alzheimer’s disease took on heightened interest with passage of the National Alzheimer’s Project Act (NAPA). Signed into law in January 2011, the Act called for a coordinated National Plan to accelerate research and improve care and services for people living with Alzheimer's and related dementias, and their families.
Efforts under the National Plan are guided by an Advisory Council on Alzheimer’s Research, Care, and Services, consisting of some of the nation’s foremost experts, convened by the Secretary of the U.S. Department of Health and Human Services. With the advisory council’s guidance and public input, the first National Plan to Address Alzheimer’s Disease was created in 2012.
The plan lays out six ambitious goals to both prevent future cases of Alzheimer's and related dementias and to better meet the needs of the millions of American families currently facing these diseases:
- Prevent and effectively treat Alzheimer's and related dementias by 2025
- Enhance care quality and efficiency
- Expand supports for people with Alzheimer's and related dementias and their families
- Enhance public awareness and engagement
- Improve data to track progress
- Accelerate action to promote healthy aging and reduce risk factors for Alzheimer’s and related dementias
NIH leads the research effort on the first goal, targeted at preventing and treating the disease. Updated annually, the research component of the National Plan is a collaborative, evolving framework. It outlines the basic, translational, and clinical research needed to understand and conquer Alzheimer’s and related dementias. In support of the research goals of the Plan, NIH embarked on an ambitious strategic planning process that engaged key stakeholders and resulted in the development of implementation milestones and success criteria.
The National Institute on Aging (NIA), which oversees NIH research on Alzheimer’s, led the development of implementation research milestones in collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) and other NIH Institutes, Centers, and Offices, as well as with extensive input from a variety of sources and perspectives outside of NIH. Central to this process are a series of research summits organized by NIH that bring together leading experts and innovators from academia, industry, and advocacy groups.
- Alzheimer’s Disease Research Summit 2012: Path to Treatment and Prevention
- Alzheimer's Disease-Related Dementias (ADRD): Research Challenges and Opportunities 2013 Summit
- Alzheimer’s Disease Research Summit 2015: Path to Treatment and Prevention
- Alzheimer’s Disease-Related Dementias 2016 Summit
- National Research Summit on Care, Services, and Supports for Persons with Dementia and Their Caregivers in 2017
- NIH Alzheimer’s Disease Research Summit 2018: Path to Treatment and Prevention
- Alzheimer's Disease-Related Dementias Summit 2019: Research Challenges and Opportunities
- Summit Virtual Meeting Series: 2020 National Research Summit on Care, Services, and Supports for Persons with Dementia and Their Caregivers
- 2021 NIH Alzheimer's Disease Research Summit: Path to Precision Medicine for Treatment and Prevention
- Alzheimer's Disease-Related Dementias (ADRD) Summit 2022
Annual Bypass Budget Proposals
Starting in 2015, congressional legislation required that NIH prepare a professional judgment budget to estimate the additional funding needed each year to help reach the ultimate research goal of the National Plan — to effectively treat and prevent Alzheimer’s and related dementias by 2025.
NIH submits this report to the President annually through FY 2025, for review and transmittal to Congress. Only two other areas of biomedical research — cancer and HIV/AIDS — have been the subject of such special NIH budget development aimed at speeding discovery. This approach is often referred to as a “bypass budget” because of its direct transmission to the President and then to Congress without modification through the traditional Federal budget process.
NIH welcomes this annual opportunity to develop a budget for expanding research on Alzheimer’s and related dementias — based on a carefully considered roadmap that moves us toward ending the tremendous physical, emotional, and financial devastation wrought by these fatal disorders.
Read the latest NIH Bypass Budget proposal for Alzheimer's and related dementias.